A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide

Br J Cancer. 1992 Feb;65(2):267-70. doi: 10.1038/bjc.1992.53.

Abstract

Multidrug resistance (MDR) is one of the mechanisms of resistance to multiple cytotoxic drugs and is mediated by the expression of a membrane pump called the P-glycoprotein. Nifedipine is one of the calcium channel blocking agents which reverses MDR in vitro. Fifteen patients with various malignancies received nifedipine at three dose levels: 40 mg, 60 mg and 80 mg orally twice daily for 6 days. Etoposide was administered intravenously on day 2 in a dose of 150-250 mg m-2 and orally 150-300 mg twice daily on days 3 and 4. Cardiovascular effects of nifedipine were dose limiting and the maximum tolerated dose was 60 mg bid. Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively. Nifedipine did not interfere with the pharmacokinetics of etoposide.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Drug Administration Schedule
  • Drug Evaluation
  • Drug Interactions
  • Drug Resistance*
  • Etoposide / pharmacokinetics
  • Etoposide / therapeutic use*
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Nifedipine / administration & dosage*
  • Nifedipine / adverse effects
  • Nifedipine / pharmacokinetics

Substances

  • Etoposide
  • Nifedipine